Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OCULAR THERAPEUTIX, INC (OCUL)

Ocular Therapeutix Q2 net loss widens to $78.8 million; revenue flat at $13.5 million

Negative Impact 3 of 5 earnings Written later

Ocular Therapeutix reported second quarter 2026 results with a net loss of $78.8 million, up from $67.8 million a year earlier, while total net revenue was flat at $13.5 million. The company said its AXPAXLI NDA submission for wet AMD remains on track for Q4 2026 and that its cash balance of $598.6 million supports operations into 2028, though higher spending lifts the loss.

Key points

  • Net loss of $78.8 million, or $0.35 per share, versus a net loss of $67.8 million, or $0.39 per share, in Q2 2025
  • Total net revenue of $13.5 million, flat year over year
  • R&D expenses rose to $54.1 million from $51.1 million, and G&A rose to $22.2 million from $14.3 million
  • Cash and cash equivalents of $598.6 million as of June 30, 2026, with runway expected into 2028

The filing

CompanyOCULAR THERAPEUTIX, INC (OCUL)
Form8-K, current report
Filed with the SECAug 3, 2026, 7:07 AM ET
Accession number0001104659-26-089443

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.